KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.

Anwaar Saeed, Josep Tabernero, Aparna Parikh, Marc Van den Eynde, Meinolf Karthaus, Marco Gerlinger, Zhong Wang, Guan Wang, Robina Smith, J Randolph Hecht

Future Oncol 20(24) 1733-1743

PMID39041200
PMCIDPMC11485978
DOI10.1080/14796694.2024.2352276
发表日期2024-07-23
摘要

摘要

Most patients with metastatic colorectal cancer (mCRC) have limited treatment options following standard-of-care therapy. VEGFR-tyrosine kinase inhibitors (TKIs) have demonstrated clinical activity in mCRC in combination with immune checkpoint inhibitors (ICIs), particularly in patients without liver metastases. The TKI zanzalintinib (XL092) targets VEGFR, MET and TAM kinases, proteins that are involved in tumor growth, angiogenesis, metastasis and immunosuppression. Zanzalintinib has immunomodulatory properties that may enhance response to ICIs. Presented is the design of STELLAR-303, a global, phase III, open-label, randomized study evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with non-MSI-H mCRC who progressed during/after or are refractory/intolerant to standard-of-care therapy. The primary end point is overall survival in patients without liver metastases.Clinical Trial Registration: NCT05425940 (ClinicalTrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。